The Push–Pull of Industry in Interventional Cardiovascular Trials

Patrice Wendling

June 03, 2020

One in five trials (16.2%) were not prospectively registered before the start of enrollment, and at least one major discrepancy existed between the registered and published primary outcome in 38% of registered trials.

Click here to learn more about the article

Type of Sponsorship Associated with Differences Between Trials for Invasive Cardiovascular Treatments

Mario Gaudino, ROMA Trial, CABG, Invasive Cardiovascular Treatments, cardiovascular diseaseIn randomized clinical trials, commercial sponsorship influences how studies are designed and the results reported in ways that often benefit the study’s sponsor, Weill Cornell...

Read More

Recent invasive CV trials fall short on certain design aspects

Contemporary randomized clinical trials assessing invasive CV interventions are often small with short follow-up and limited power to identify large treatment effects, according to a study published in JAMA Internal Medicine.

The study also found that commercially supported trials were linked to differences in results, design and reporting. In particular, commercially supported trials were more likely to report favorable outcomes than other trials, and to report findings...

Read More